CDT Equity Inc. Reports $39.2 Million Net Loss and Strategic Developments in 10-K Filing

CDT Equity Inc., formerly known as Conduit Pharmaceuticals Inc., reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company recorded a net loss of $39.2 million, a substantial increase from the $17.8 million loss reported in the previous year. This increase in losses is attributed to heightened research and development expenses, which rose by 50% to approximately $5.1 million, primarily due to costs associated with agreements with Sarborg Limited and other consulting services. General and administrative expenses also surged by 163% to $31.7 million, largely driven by litigation liabilities and compensation expenses related to the issuance of common stock.

In terms of strategic developments, CDT Equity has made notable advancements in its clinical pipeline, which includes candidates targeting autoimmune disorders and idiopathic male infertility. The company has entered into a licensing agreement with AstraZeneca for the development of glucokinase activators AZD1656 and AZD5658, as well as the myeloperoxidase inhibitor AZD5904. These assets are positioned for further development and commercialization, with the company aiming to leverage its partnerships to enhance its research capabilities and expedite the drug development process.

Operationally, CDT Equity has focused on expanding its research capabilities through collaborations, particularly with Sarborg, which provides AI-driven insights to optimize drug development. The company has also established a partnership with Manoira Corporation to explore veterinary applications of its clinical assets, thereby diversifying its revenue streams. As of December 31, 2025, the company employed four full-time staff members and relied on various consultants and third-party organizations for its research and development activities.

Looking ahead, CDT Equity faces challenges in securing additional funding to support its operations and clinical trials. The company has expressed substantial doubt regarding its ability to continue as a going concern without raising further capital. Management anticipates needing approximately $10 million for working capital over the next 12 months, which includes ongoing operational expenses and obligations related to its convertible notes. The company plans to pursue various financing options, including equity and debt offerings, but acknowledges the uncertainty surrounding the availability of such funding on favorable terms.

In summary, while CDT Equity Inc. is advancing its clinical pipeline and establishing strategic partnerships, it faces significant financial challenges and uncertainties regarding future funding. The company's ability to navigate these challenges will be critical to its long-term success and operational viability.